Skip to content
news
Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results...
Oct 10, 2024
Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize...
Oct 8, 2024
Lipocine to Host Virtual KOL Event on LPCN 2401 for...
Oct 2, 2024
Company
About Lipocine
Management
Board of Directors
Corporate Governance
Careers
Pipeline & Product
Pipeline
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
LPCN 1154 – Postpartum Depression
LPCN 2201 – Major Depressive Disorder
LPCN 2101 – Epilepsy
LPCN 2203 – Essential Tremor
LPCN 1148 – Management of Liver Cirrhosis
LPCN 2401 – Obesity Management
LPCN 1107 – Prevention of Preterm Birth
Product
TLANDO®
TLANDO®
Investors/Media
Overview
Press Releases
Events
Presentations
Financials & Filings
Stock Information
Investor FAQs
Contact
Address & Inquiries
Business Development
Linkedin-in
Search
October 2, 2024
Innovating beyond
boundaries for patients